Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Liabilities (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Total Liabilities data on record, last reported at $8.7 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 81.24% year-over-year to $8.7 million; the TTM value through Sep 2025 reached $8.7 million, down 81.24%, while the annual FY2024 figure was $36.3 million, 429.03% up from the prior year.
  • Total Liabilities reached $8.7 million in Q3 2025 per CRVS's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $46.4 million in Q3 2024 and bottomed at $6.7 million in Q1 2024.
  • Average Total Liabilities over 4 years is $14.3 million, with a median of $10.1 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: soared 506.38% in 2024, then crashed 81.24% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $12.1 million in 2022, then tumbled by 43.35% to $6.9 million in 2023, then soared by 429.03% to $36.3 million in 2024, then crashed by 76.04% to $8.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $8.7 million in Q3 2025, $9.2 million in Q2 2025, and $10.1 million in Q1 2025.